Dr. Mark Hyman Longevity Protocol Compared to Similar Public Figures

Who Is Dr. Mark Hyman and Why Does His Protocol Matter?

Dr. Mark Hyman is a board-certified family medicine physician who led the Cleveland Clinic Center for Functional Medicine for nearly a decade. He has publicly disclosed using testosterone replacement therapy, targeted supplementation, and dietary strategies designed to extend healthspan. His visibility makes him one of the most-watched figures in the longevity space.

From Cleveland Clinic to Longevity Advocate

Hyman practiced conventional medicine before shifting toward functional medicine in the early 2000s. He served as head of the Cleveland Clinic's Center for Functional Medicine from 2014 to 2022, a role that gave institutional credibility to an otherwise polarizing field. His 2023 book "Young Forever" laid out his personal longevity framework, built on what he calls the "hallmarks of aging" applied through functional medicine diagnostics [1].

The Functional Medicine Lens

Functional medicine prioritizes identifying root causes of disease rather than managing symptoms. The Institute for Functional Medicine defines the approach as "a systems biology-based approach that focuses on identifying and addressing the root cause of disease" [2]. This orientation shapes every element of Hyman's protocol, from his lab panel choices (fasting insulin, hs-CRP, homocysteine) to his preference for food-based interventions before pharmaceuticals. It also explains why his regimen looks different from peers who start from a pharmacology-first position.

Hyman's Disclosed Longevity Stack

Hyman has been more transparent than many physician-influencers about what he personally takes. His protocol spans hormones, supplements, dietary patterns, and exercise.

Testosterone Replacement Therapy

Hyman has stated publicly in podcast interviews that he uses testosterone replacement therapy. The Endocrine Society's 2018 clinical practice guidelines recommend TRT for men with symptomatic hypogonadism confirmed by morning total testosterone levels below 300 ng/dL on two separate occasions [3]. Hyman, now in his mid-60s, falls within the demographic where age-related testosterone decline is well-documented. A 2007 longitudinal study in the Journal of Clinical Endocrinology & Metabolism found that total testosterone declines approximately 1.6% per year after age 40 [4].

Supplement Protocol

Hyman's disclosed supplement regimen includes high-dose omega-3 fatty acids (EPA/DHA), vitamin D3 (typically 5,000 IU daily), magnesium glycinate, methylated B vitamins (methylfolate and methylcobalamin), and a polyphenol-rich multivitamin. A 2019 meta-analysis in the BMJ found that omega-3 supplementation reduced cardiovascular mortality risk by 8% (RR 0.92, 95% CI 0.86 to 0.98) [5]. Hyman has also discussed using NAD+ precursors such as NMN, citing preclinical data suggesting improved mitochondrial function, though human trial data remains limited [6].

The Pegan Diet

Hyman coined the term "pegan" to describe a hybrid of paleo and vegan eating patterns. The diet emphasizes vegetables (75% of the plate), healthy fats from avocado and olive oil, moderate animal protein from grass-fed and wild-caught sources, and strict avoidance of refined sugar, dairy, and gluten. He has stated: "Food is the most powerful drug on the planet. It can cause or cure most diseases." While no randomized trial has tested the pegan diet specifically, its components align with evidence supporting Mediterranean-style eating patterns, which a 2018 Cochrane review associated with reduced cardiovascular events (RR 0.72, 95% CI 0.57 to 0.93) [7].

Exercise and Recovery

Hyman has described a training regimen that includes strength training three to four times per week, zone 2 cardiovascular exercise (walking, cycling), and regular sauna use. He has referenced the 2022 prospective cohort study in the British Journal of Sports Medicine showing that 30 to 60 minutes per week of muscle-strengthening activity was associated with a 10 to 20% lower risk of all-cause mortality [8].

Peter Attia: The Quantified Clinician

Peter Attia, MD, trained in surgical oncology at Johns Hopkins before founding Early Medical, a longevity-focused practice. His 2023 book "Outlive" became a bestseller and outlined a framework he calls "Medicine 3.0."

Where Attia and Hyman Overlap

Both physicians emphasize metabolic health as the foundation of longevity. Both track fasting insulin, use continuous glucose monitors, and consider cardiovascular disease the leading threat to healthspan. Both have discussed using hormone optimization in clinical practice.

Where They Diverge

Attia's framework is more pharmacologically aggressive. He has publicly discussed using rapamycin (sirolimus) off-label for its potential geroprotective effects, citing preclinical data from the National Institute on Aging's Interventions Testing Program showing a 9 to 14% increase in median lifespan in mice [9]. Hyman has not disclosed rapamycin use. Attia also places greater emphasis on VO2 max testing and high-intensity interval training, while Hyman leans toward zone 2 work and recovery modalities.

Attia's approach could be characterized as "engineer the system," while Hyman's is closer to "remove what's breaking the system." Both arrive at similar biomarker targets through different clinical philosophies.

Lipid Management

Attia has been outspoken about aggressive apoB-lowering, stating in interviews: "I think apoB is the most important modifiable risk factor for cardiovascular disease." He has discussed using statins and PCSK9 inhibitors in patients with elevated apoB. Hyman tends to favor dietary and supplement-based lipid management first, reserving pharmaceuticals for cases where functional interventions are insufficient. The 2017 European Atherosclerosis Society consensus panel recommended apoB measurement as a more accurate marker of atherogenic particle burden than LDL-C alone [10].

David Sinclair: The Molecular Biologist

David Sinclair, PhD, is a professor of genetics at Harvard Medical School whose research focuses on sirtuins, NAD+ biology, and epigenetic reprogramming. His 2019 book "Lifespan" popularized the "information theory of aging."

The NMN and Resveratrol Focus

Sinclair has publicly disclosed taking NMN (1 gram daily) and resveratrol (1 gram daily, mixed with yogurt for fat-soluble absorption). His lab published data in Cell in 2013 showing that one week of NMN treatment reversed age-related mitochondrial decline in aged mice [6]. Human data is emerging but not yet definitive. A 2022 randomized controlled trial published in Science found that NMN (250 mg daily for 12 weeks) increased blood NAD+ levels by approximately 38% in healthy middle-aged adults, but clinical endpoint data on mortality or disease prevention remains absent [11].

Where Sinclair Differs from Hyman

Sinclair's protocol is molecule-first. He builds his regimen around specific compounds targeting defined molecular pathways (sirtuins, AMPK, mTOR). Hyman builds his around systems-level diagnostics, treating the patient's unique pattern of dysfunction. Sinclair has also disclosed taking metformin 1 gram daily as a potential geroprotective agent, citing the TAME (Targeting Aging with Metformin) trial rationale [12]. Hyman has discussed metformin's role in insulin resistance but has not publicly stated he takes it for longevity purposes.

Criticism and Controversy

Sinclair's supplement disclosures have drawn scrutiny. A 2024 review in Nature Aging noted that "translating findings from short-lived model organisms to human longevity requires caution, as the dose-response relationships and pharmacokinetics differ substantially" [13]. Hyman has been less publicly tied to specific molecules and more to a broad systems approach, though his functional medicine framework has its own critics who question the evidence base for some diagnostic panels.

Bryan Johnson: The Algorithm-Driven Biohacker

Bryan Johnson, the tech entrepreneur behind Project Blueprint, represents the most extreme end of the longevity-figure spectrum. He spends over $2 million annually on a protocol managed by a team of 30+ physicians, and he tracks over 100 biomarkers monthly.

Scale of Intervention

Johnson's regimen includes over 100 daily supplements, prescription medications (metformin, acarbose, rapamycin, testosterone, DHEA), plasma exchange, gene therapy experiments, and caloric restriction to approximately 1,950 calories per day. He publishes his biomarker data publicly and has reported a biological age approximately 5 years younger than his chronological age using DNA methylation clocks [14].

The Philosophical Gap

Hyman and Johnson occupy opposite poles. Hyman's philosophy centers on accessible, food-first medicine designed for broad clinical populations. Johnson's is an n=1 experiment with a budget and monitoring infrastructure unavailable to virtually anyone else. Hyman has commented on this contrast, noting that longevity should not require wealth to be effective.

Reproducibility Concerns

A 2023 commentary in The Lancet observed that "individualized anti-aging regimens based on biomarker optimization lack standardized protocols, making it difficult to evaluate efficacy or safety at a population level" [15]. Johnson's approach, while generating remarkable biomarker data, has no control group and no peer-reviewed outcome data. Hyman's approach, while less dramatic in its claims, aligns more closely with evidence-based medicine traditions.

Andrew Huberman: The Neuroscience Communicator

Andrew Huberman, PhD, is a Stanford neuroscience professor whose podcast has made him one of the most influential voices in health optimization. His longevity-adjacent protocols focus heavily on sleep, light exposure, and cold/heat therapy.

The Behavioral Emphasis

Huberman's protocol is notably light on pharmaceuticals compared to Attia, Sinclair, or Johnson. He emphasizes morning sunlight exposure for circadian rhythm optimization, deliberate cold exposure (citing catecholamine release data), and a supplement stack that includes omega-3s, magnesium threonate, theanine, and apigenin for sleep. A 2022 study in Cell Reports Medicine showed that consistent sleep duration of 7 to 8 hours was associated with a 30% reduction in all-cause mortality risk compared to irregular sleep patterns [16].

Comparison to Hyman

Hyman and Huberman share an emphasis on behavioral and nutritional foundations before pharmaceuticals. Both prioritize sleep quality and stress management. The key difference is clinical depth. Hyman orders extensive lab work (insulin, hs-CRP, homocysteine, organic acids, heavy metals) and titrates interventions based on individual results. Huberman's public recommendations are population-level behavioral protocols, not individualized clinical prescriptions.

How These Protocols Compare on Key Domains

Each figure prioritizes different levers within the longevity toolkit. Hyman stands out for his balanced approach across nutrition, hormones, and diagnostics, with less reliance on experimental compounds than some peers.

Hormones

Hyman and Attia both use or prescribe TRT in appropriate clinical contexts. Johnson uses testosterone and DHEA within his Blueprint protocol. Sinclair and Huberman have not publicly disclosed hormone replacement use. The Endocrine Society's guidelines support TRT in men with confirmed hypogonadism and symptoms, while noting that risks include erythrocytosis and potential cardiovascular effects requiring monitoring [3].

Diet and Nutrition

Hyman's pegan diet is the most prescriptive dietary model in this comparison group. Attia follows a flexible macronutrient approach with periodic fasting. Johnson eats a fixed 1,950-calorie menu with no variation. Sinclair practices time-restricted eating. Huberman has discussed various dietary approaches without committing to a single framework.

Pharmaceuticals and Supplements

Johnson takes the most supplements (100+). Sinclair takes a focused stack of 5 to 7 molecules targeting specific pathways. Attia uses pharmaceuticals (statins, rapamycin) selectively based on biomarkers. Hyman's stack is moderate (10 to 15 supplements) and food-forward. A 2021 systematic review in Annals of Internal Medicine found insufficient evidence to recommend most supplements for chronic disease prevention in the general population, though specific deficiencies warranted targeted supplementation [17].

Monitoring and Diagnostics

All five figures use advanced diagnostics, but the depth varies. Johnson tracks 100+ biomarkers monthly. Attia runs comprehensive panels quarterly. Hyman orders functional medicine panels including organic acids, stool analysis, and nutrient levels. Sinclair and Huberman rely primarily on standard blood work and wearable data.

What Patients Can Learn from These Comparisons

The diversity among these public figures illustrates that there is no single "longevity protocol." Dr. Robert Lufkin, a clinical professor of radiology at USC, has noted: "The longevity field is still in its infancy. We have promising signals from multiple approaches, but no single intervention has been proven to extend human lifespan in a randomized trial."

Start with the Basics

Across all five figures, certain fundamentals are consistent: metabolic health monitoring, regular exercise including resistance training, sleep optimization, and stress management. These interventions have the strongest evidence base. A 2022 prospective study in JAMA Internal Medicine (N=116,221) found that adherence to five lifestyle factors (diet, exercise, moderate alcohol, nonsmoking, healthy BMI) was associated with an additional 12 to 14 years of life expectancy at age 50 [18].

Individualization Matters

Hyman's core argument, that interventions should be tailored to an individual's unique biology through comprehensive testing, aligns with the direction of precision medicine. The National Institutes of Health's All of Us Research Program aims to gather health data from one million participants specifically to enable this kind of individualized approach [19]. Patients considering any longevity protocol should work with a qualified clinician to interpret lab results and adjust interventions based on their own risk factors, genetics, and goals.